Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms
Authors:
Open Access
- 3 March 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Abstract
The current study evaluated the effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and investigated its possible mechanisms. 124 patients were randomized to receive 25 mg empagliflozin QD, or placebo double blind for 12 weeks. Patients underwent 24-h ABPM. Endothelial function and arterial stiffness were also measured prior to randomization and at week 12. At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP was − 8.14 mmHg (95% CI − 10.32, − 3.96,P = 0.005). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP was − 5.27 mmHg (95% CI − 8.19, − 1.35,P < 0.001). Changes in office BP were consistent with ABPM. Empagliflozin was well tolerated. Empagliflozin was associated with significant and clinically meaningful reductions in BP versus placebo in Chinese elderly patients with type 2 diabetes and hypertension. The underlying mechanisms possiblely at least in part were the improvements of endothelial function and arterial stiffness associated with empagliflozin.Registration number: ChiCTR2100054678, Registration date: December 23, 2021.Keywords
Funding Information
- Health Commission of Jiangxi Province (202130028)
This publication has 27 references indexed in Scilit:
- Cardiovascular Outcomes in Framingham Participants With DiabetesHypertension, 2011
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humansKidney International, 2011
- Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart StudyTrends in Cardiovascular Medicine, 2010
- Blood Pressure Variables and Cardiovascular RiskHypertension, 2009
- Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 DiabetesNew England Journal of Medicine, 2008
- Aortic Diameter, Aortic Stiffness, and Wave Reflection Increase With Age and Isolated Systolic HypertensionHypertension, 2005
- Arterial Stiffness and HypertensionHypertension, 2005
- Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes MellitusNew England Journal of Medicine, 2000
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 1998
- Insulin Resistance and Hypertension in the ElderlyDrugs & Aging, 1994